Search

Your search keyword '"Panaccione, Remo"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Panaccione, Remo" Remove constraint Author: "Panaccione, Remo" Journal the lancet gastroenterology & hepatology Remove constraint Journal: the lancet gastroenterology & hepatology
19 results on '"Panaccione, Remo"'

Search Results

2. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

3. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

4. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study

5. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

6. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

7. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

8. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

10. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

11. Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease

13. Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development

14. Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

15. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

16. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

17. Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease

19. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period

Catalog

Books, media, physical & digital resources